Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

The UK government starts a trial offering weight loss drug Mounjaro to unemployed obese individuals to improve health and ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

A major trial is coming to Greater Manchester to see how a new drug can tackle obesity. The ‘five-year real-world evidence study’ will be run by Health Innovation Manchester and pharmaceutical giant ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Eli Lilly (NYSE: LLY) has partnered with the UK government, investing £279 million ($340 million) to address public health ...